Mostrar el registro sencillo del ítem

dc.contributor.authorGonzález Juanatey, Carlos 
dc.contributor.authorAnguita-Sánchez, M.
dc.contributor.authorBarrios, V.
dc.contributor.authorNúñez-Gil, I.
dc.contributor.authorGómez-Doblas, J.J.
dc.contributor.authorGarcía-Moll, X.
dc.contributor.authorLafuente-Gormaz, C.
dc.contributor.authorRollán-Gómez, M.J.
dc.contributor.authorPeral-Disdier, V.
dc.contributor.authorMartínez-Dolz, L.
dc.contributor.authorRodríguez-Santamarta, M.
dc.contributor.authorViñolas-Prat, X.
dc.contributor.authorSoriano-Colomé, T.
dc.contributor.authorMuñoz-Aguilera, R.
dc.contributor.authorPlaza, I.
dc.contributor.authorCurcio-Ruigómez, A.
dc.contributor.authorOrts-Soler, E.
dc.contributor.authorSegovia, J.
dc.contributor.authorFanjul, V.
dc.contributor.authorCequier, Á.
dc.date.accessioned2025-08-26T11:35:09Z
dc.date.available2025-08-26T11:35:09Z
dc.date.issued2022
dc.identifier.citationGonzález-Juanatey C, Anguita-Sánchez M, Barrios V, Núñez-Gil I, Gómez-Doblas JJ, García-Moll X, et al. Major Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing. Journal of Clinical Medicine. 2022;11(20).
dc.identifier.issn2077-0383
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/637951b10b78045a77807d10*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20945
dc.description.abstractPatients with Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are at high risk of developing major adverse cardiovascular events (MACE). This is a multicenter, retrospective, and observational study performed in Spain aimed to characterize these patients in a real-world setting. Unstructured data from the Electronic Health Records were extracted by EHRead®, a technology based on Natural Language Processing and machine learning. The association between new MACE and the variables of interest were investigated by univariable and multivariable analyses. From a source population of 2,184,662 patients, we identified 4072 adults diagnosed with T2DM and CAD (62.2% male, mean age 70 ± 11). The main comorbidities observed included arterial hypertension, hyperlipidemia, and obesity, with metformin and statins being the treatments most frequently prescribed. MACE development was associated with multivessel (Hazard Ratio (HR) = 2.49) and single coronary vessel disease (HR = 1.71), transient ischemic attack (HR = 2.01), heart failure (HR = 1.32), insulin treatment (HR = 1.40), and percutaneous coronary intervention (PCI) (HR = 2.27), whilst statins (HR = 0.73) were associated with a lower risk of MACE occurrence. In conclusion, we found six risk factors associated with the development of MACE which were related with cardiovascular diseases and T2DM severity, and treatment with statins was identified as a protective factor for new MACE in this study.en
dc.description.sponsorshipThis study was funded by AstraZeneca Spain (Externally Sponsored Scientific Research, ESR-18-13815) and sponsored by the Spanish Society of Cardiology.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleMajor Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing*
dc.typeArticleen
dc.authorsophosGonzález-Juanatey, Á C.
dc.authorsophosAnguita-Sánchez, M.
dc.authorsophosBarrios, V.
dc.authorsophosNúñez-Gil, I.
dc.authorsophosGómez-Doblas, J. J.
dc.authorsophosGarcía-Moll, X.
dc.authorsophosLafuente-Gormaz, C.
dc.authorsophosRollán-Gómez, M. J.
dc.authorsophosPeral-Disdier, V.
dc.authorsophosMartínez-Dolz, L.
dc.authorsophosRodríguez-Santamarta, M.
dc.authorsophosViñolas-Prat, X.
dc.authorsophosSoriano-Colomé, T.
dc.authorsophosMuñoz-Aguilera, R.
dc.authorsophosPlaza, I.
dc.authorsophosCurcio-Ruigómez, A.
dc.authorsophosOrts-Soler, E.
dc.authorsophosSegovia, J.
dc.authorsophosFanjul, V.
dc.authorsophosCequier
dc.identifier.doi10.3390/jcm11206004
dc.identifier.sophos637951b10b78045a77807d10
dc.issue.number20
dc.journal.titleJournal of Clinical Medicine*
dc.relation.projectIDAstraZeneca Spain [ESR-18-13815]; Spanish Society of Cardiology
dc.relation.publisherversionhttps://www.mdpi.com/2077-0383/11/20/6004/pdf?version=1665630847;https://mdpi-res.com/d_attachment/jcm/jcm-11-06004/article_deploy/jcm-11-06004-v3.pdf?version=1665630847es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Lugoes
dc.subject.keywordHULAes
dc.subject.keywordIDISes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number11


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional